Perrigo gets FDA nod for generic Zovirax
Perrigo has received the Food and Drug Administration’s blessing for its generic version of Zovirax cream (acyclovir 5%).
The product, which was developed in collaboration with Sol-Gel Technologies, is an antiviral for cold sores and a generic of GlaxoSmithKline's branded product. Perrigo said it is expected to launch this month.
Zovirax had a market value of roughly $92 million for the twelve months ending December 2018, according to IQVIA.
"This final approval and first to market launch is another example of our long-term investment in new products, the team's impressive execution skills and our solid collaboration with SolGel. We stay committed to providing affordable treatment options for patients in important extended topical categories," Perrigo executive vice president and Rx pharmaceuticals president Sharon Kochan said.
The product, which was developed in collaboration with Sol-Gel Technologies, is an antiviral for cold sores and a generic of GlaxoSmithKline's branded product. Perrigo said it is expected to launch this month.
Zovirax had a market value of roughly $92 million for the twelve months ending December 2018, according to IQVIA.
"This final approval and first to market launch is another example of our long-term investment in new products, the team's impressive execution skills and our solid collaboration with SolGel. We stay committed to providing affordable treatment options for patients in important extended topical categories," Perrigo executive vice president and Rx pharmaceuticals president Sharon Kochan said.